Proactive Investors - Run By Investors For Investors

Motif Bio launches accelerated book-build placing to raise approximately £10mln to boost iclaprim investments

The AIM-listed biopharmaceutical company said the monies raised will be used to fund near-term regulatory and pre-commercial investments for iclaprim, its novel antibiotic candidate, and to strengthen the company's balance sheet
Antibiotics
The cash injection will be used to fund regulatory and pre-commercial investments for iclaprim, its next-generation antibiotic

Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) has launched a conditional placing, to raise approximately £10mln (US$14mln), from new and existing investors via an accelerated book-build.

The AIM-listed drug developer company said the monies raised will be used to fund near-term regulatory and pre-commercial investments for iclaprim, its next-generation antibiotic, and to strengthen the company's balance sheet.

READ: Motif Bio makes senior clinical development hire

Graham Lumsden, Motif Bio’s chief executive officer, said: “This funding, along with our existing resources, allows us to fund some regulatory and pre-commercialisation investments for iclaprim and strengthen our balance sheet ahead of entering into more advanced discussions with potential partners to commercialise iclaprim in the U.S. and elsewhere."

iclaprim is being developed to treat acute bacterial skin and skin structure infections (ABSSSI).

It passed a major milestone last year when it successfully concluded a second phase III clinical trial and in March initiated a rolling submission to the US Food and Drug Administration, while also preparing a marketing authorisation application to the European Medicines Agency.

The submission is expected to be completed in the second quarter of 2018.

Gram-positive 

The drug is a gram-positive antibiotic targeted especially to those who may have impaired kidneys, and/or face other compromising factors, such as diabetes.

It is estimated that up to 26% of the 3.6mln patients hospitalized annually with acute bacterial skin and skin structure infections have kidney disease.

Antibiotics are the most commonly prescribed class of drug, representing a global market of US$40bn. New, innovative approaches are needed, due to ever-evolving drug-resistant strains of bacteria. 

The global market for antibiotic drugs targeting difficult-to-treat infections, such as ABSSSI, is an estimated US$3bln and is dominated by vancomycin, a traditional first-line treatment.

 

View full MTFB profile View Profile

Motif Bio Plc Timeline

Related Articles

mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
A paper plane about to be launched with the help of surgical scissors
November 13 2018
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.
skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use